S 81694 Plus Paclitaxel in Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Metastatic Triple Negative Breast Cancer
Interventions: DRUG: Combination therapy (S81694 + paclitaxel) phase I|DRUG: Paclitaxel|DRUG: Combination therapy (S81694 + paclitaxel) phase II
Sponsor: Institut de Recherches Internationales Servier
Collaborators: ADIR, a Servier Group company